The board have been kicking a lot of goals lately with another piece to the puzzle squared away here.
Tony Keating has the experience in commercialising medical technology on the ASX which is hard to come by. He made a lot of money for shareholders of Resapp.
The fact that he sold Resapp to Pfizer for $180m means that he has the runs on the board in crystalising real value for shareholders.
Also, there are a huge number of medical technology businesses on the ASX in the diagnosis space and he has been happy to put his name to this in the public spere. This says a lot for where he believes this company can go.
With the share price at $0.036 the market cap is still only $15m, thats a huge amount of leverage to the upside.
